Luc J. J. Derijks

Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease

Marieke J. H. Coenen, Dirk J. de Jong, Corine J. van Marrewijk et al. · Gastroenterology · 2015 · 193 citations · Full text

Inflammation, Autoimmune Disease, Hematology +7

Inosine Triphosphate Pyrophosphatase and Thiopurine S-Methyltransferase Genotypes Relationship to Azathioprine-Induced Myelosuppression

Zuzana Zelinková, Luc J. J. Derijks, Pieter Stokkers et al. · Clinical Gastroenterology and Hepatology · 2006 · 152 citations · Full text

Inosine Triphosphate Pyrophosphatase, Medicine, Genetics +4

Pharmacokinetics of 6-Mercaptopurine in Patients with Inflammatory Bowel Disease

Luc J. J. Derijks, Lennard P. L. Gilissen, L.G.J.B. Engels et al. · Therapeutic Drug Monitoring · 2004 · 121 citations

Red Blood Cell, Gastrointestinal Pharmacology, Tpmt Genotype +8

6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients

Luc J. J. Derijks, Dirk J. de Jong, Lennard PL Gilissen et al. · European Journal of Gastroenterology & Hepatology · 2003 · 74 citations

Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study

E.M.H. Schmitz, Paul J. Boekema, Jan-Willem Straathof et al. · Alimentary Pharmacology & Therapeutics · 2017 · 70 citations · Full text